HomeCompareSGIOY vs DIVO

SGIOY vs DIVO: Dividend Comparison 2026

SGIOY yields 1.82% · DIVO yields 6.49%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SGIOY wins by $611.0K in total portfolio value· pulled ahead in Year 4
10 years
SGIOY
SGIOY
● Live price
1.82%
Share price
$11.09
Annual div
$0.20
5Y div CAGR
70.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$641.7K
Annual income
$420,841.59
Full SGIOY calculator →
DIVO
DIVO
● Live price
6.49%
Share price
$44.85
Annual div
$2.91
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$981.68
Full DIVO calculator →

Portfolio growth — SGIOY vs DIVO

📍 SGIOY pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSGIOYDIVO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SGIOY + DIVO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SGIOY pays
DIVO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SGIOY
Annual income on $10K today (after 15% tax)
$154.36/yr
After 10yr DRIP, annual income (after tax)
$357,715.35/yr
DIVO
Annual income on $10K today (after 15% tax)
$552.00/yr
After 10yr DRIP, annual income (after tax)
$834.43/yr
At 15% tax rate, SGIOY beats the other by $356,880.92/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SGIOY + DIVO for your $10,000?

SGIOY: 50%DIVO: 50%
100% DIVO50/50100% SGIOY
Portfolio after 10yr
$336.2K
Annual income
$210,911.64/yr
Blended yield
62.73%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SGIOY buys
0
DIVO buys
0
No recent congressional trades found for SGIOY or DIVO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSGIOYDIVO
Forward yield1.82%6.49%
Annual dividend / share$0.20$2.91
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR70.4%0%
Portfolio after 10y$641.7K$30.7K
Annual income after 10y$420,841.59$981.68
Total dividends collected$599.7K$8.2K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: SGIOY vs DIVO ($10,000, DRIP)

YearSGIOY PortfolioSGIOY Income/yrDIVO PortfolioDIVO Income/yrGap
1$11,009$309.44$11,349$649.42$340.00DIVO
2$12,323$542.53$12,833$688.83$510.00DIVO
3$14,152$967.05$14,459$727.90$307.00DIVO
4← crossover$16,912$1,768.72$16,238$766.49+$674.00SGIOY
5$21,461$3,365.93$18,179$804.47+$3.3KSGIOY
6$29,766$6,802.41$20,293$841.71+$9.5KSGIOY
7$46,875$15,024.95$22,591$878.14+$24.3KSGIOY
8$87,836$37,680.36$25,087$913.65+$62.7KSGIOY
9$206,429$112,444.03$27,791$948.18+$178.6KSGIOY
10$641,720$420,841.59$30,718$981.68+$611.0KSGIOY

SGIOY vs DIVO: Complete Analysis 2026

SGIOYStock

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Xofluza, an influenza virus drug; and Tivicay for HIV treatment. It also develops Symproic for opioid-induced constipation treatment; S-120083 for Inflammatory pain; S-010887 for Neuropathic pain; S-117957 for Insomnia; sivopixant for Neuropathic pain, Sleep Apnea Syndrome, and Refractory/unexplainedchronic cough; S-637880 for Neuropathic Low Back Pain; Zuranolone for Depression; SDT-001 for attention-deficit/hyperactivity disorder patients; BPN14770 for Fragile X syndrome and Alzheimer's disease; and S-237648 and S-309309 for Obesity. In addition, the company develops ADR-001 for Decompensated liver cirrhosis; S-723595 for NASH; S-588410 for Esophageal and Bladder cancer; S-488210 for Head and neck squamouscell carcinoma; S-588210 for Solid tumor; S-222611 for Malignant tumor; S-770108 for Idiopathic pulmonary fibrosis; SR-0379 for Cutaneous ulcer; S-005151 for Stroke and Epidermolysis bullosa; S-531011 for Solid tumor; S-0373 for Spinocerebellar ataxia; and S-600918 and S-217622 for COVID-19, as well as S-555739 for Control of the aggravation of COVID-19. Further, it offers antibody test kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University to develop antimalarial drugs. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

Full SGIOY Calculator →

DIVOETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →
📬

Get this SGIOY vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SGIOY vs SCHDSGIOY vs JEPISGIOY vs OSGIOY vs KOSGIOY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.